{"schema_version":"secwatch.filing_event.v1","accession":"0001711279-23-000010","form_type":"8-K","ticker":"KRYS","cik":"0001711279","company_name":"Krystal Biotech, Inc.","filed_at":"2023-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.233872+00:00","generated_at":"2026-06-18T23:47:18.396748+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Krystal Biotech reports FY2022 net loss $140M; B-VEC PDUFA date May 19, 2023","bullets":["Cash, cash equivalents and investments $383.8M at Dec 31, 2022.","Net loss $140.0M for FY2022 vs $69.6M in FY2021; diluted EPS $(5.49) vs $(3.13).","B-VEC PDUFA date set for May 19, 2023; all FDA inspections complete.","Phase 3 GEM-3 trial results for B-VEC published in New England Journal of Medicine.","Plans to initiate four pipeline trials in 2023 across dermatology, respiratory, aesthetics."],"urls":{"canonical":"https://secwatch.observer/filing/0001711279-23-000010","json":"https://secwatch.observer/filing/0001711279-23-000010.json","markdown":"https://secwatch.observer/filing/0001711279-23-000010.md","text":"https://secwatch.observer/filing/0001711279-23-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711279/000171127923000010/0001711279-23-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711279/000171127923000010/krys-20230227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T23:47:18.396748+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a24e3c7cd3548f5113755422f1e29cedd1028bd9","claim":"Krystal Biotech, Inc. reported the fourth quarter ended December 31, 2022 results: net income $32.1 million, EPS $(1.25).","evidence_excerpt":"Net losses for the quarters ended December 31, 2022 and 2021 were $32.1 million and $21.8 million, or $(1.25) and $(0.94) respectively, per common share (basic and diluted).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127923000010/0001711279-23-000010-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Net income","value":"$32.1 million"},{"label":"EPS","value":"$(1.25)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"e3c7881cdaa785c5b537ab48405be76debdbb9af","claim":"Krystal Biotech, Inc. reported the year ended December 31, 2022 results: net income $140.0 million, EPS $(5.49).","evidence_excerpt":"Net losses for the years ended December 31, 2022 and 2021 were $140.0 million and $69.6 million, or $(5.49) and $(3.13), respectively, per common share (basic and diluted).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127923000010/0001711279-23-000010-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Net income","value":"$140.0 million"},{"label":"EPS","value":"$(5.49)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}